Floatz logo

Sacituzumab Tirumotecan

Myelosuppression

The First Affiliated Hospital of Xiamen Universityantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myelosuppression cohort.

Asset / SponsorPhaseRating
Docetaxel
The First Affiliated Hospital of Xiamen University
Phase 2B
Trilaciclib
The First Affiliated Hospital of Xiamen University
Phase 2B
Myelo001
Myelo Therapeutics GmbH
Phase 2B
SULANEMADLIN
Aileron Therapeutics, Inc.
Phase 1CC
EMPEGFILGRASTIM
Moscow Clinical Scientific Center
D

Same molecule, other indications

Sacituzumab Tirumotecan is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →